U.S., Nov. 10 -- ClinicalTrials.gov registry received information related to the study (NCT07925632) titled 'A Multicenter, Prospective, Observational Study of Jaktinib in Newly Diagnosed Myelofibrosis' on Nov. 04.
Brief Summary: This is a multicenter, prospective, observational clinical study designed to evaluate the real-world efficacy and safety of jaktinib in patients with newly diagnosed myelofibrosis (MF). The primary outcome measure is the proportion of patients achieving anemia response at week 24. Secondary outcome measures include MF-related symptom response rate (TSS50) at week 24, spleen volume reduction >=35% (SVR35) at week 24, progression-free survival (PFS), leukemia-free survival (LFS), overall survival (OS), and safety/to...